ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 017,90
0,76%
Dow Jones
38 675,68
1,18%
DAX
18 160,73
0,93%
Brent Oil
83,535
0,49%
Bitcoin
64 197,05
0,31%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immunome Inc (IMNM)

  7. Immunome Inc (IMNM) Actualités

IMNM Immunome Inc

15,75
0,00 (0,00%)
Avant marché
Dernière mise à jour : 13:02:23
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Immunome Inc IMNM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 15,75 13:02:23
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
15,75
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/5/202414:00BWImmunome Appoints Kinney Horn as Chief Business Officer
25/4/202414:26BWImmunome Appoints Sandra M. Swain to Board of Directors
05/4/202414:00BWImmunome to Present Preclinical Data for IM-3050, Its Lead..
28/3/202421:02BWImmunome Reports Full Year 2023 Financial Results and..
26/3/202413:00BWImmunome Completes Acquisition of AL102, a Phase 3 Asset for..
07/3/202414:00BWImmunome to Participate in the Leerink Partners Global..
01/3/202414:00BWImmunome to Participate in the TD Cowen 44th Annual..
22/2/202403:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:07EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/2/202414:15BWImmunome Recognizes Ayala Pharmaceuticals’ Announced..
16/2/202422:05BWImmunome Announces Closing of Public Offering and Full..
14/2/202422:11EDGAR2Form 8-K - Current report
14/2/202422:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/2/202404:38BWImmunome Announces Pricing of Public Offering of Common..
13/2/202422:36EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202422:10EDGAR2Form 8-K - Current report
13/2/202422:05BWImmunome Announces Proposed Public Offering of Common Stock
12/2/202420:10EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202414:05EDGAR2Form 8-K - Current report
05/2/202414:00BWImmunome to Present at the Guggenheim Healthcare Talks 6th..
02/2/202422:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
01/2/202402:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202402:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/1/202423:27EDGAR2Form 8-K - Current report
08/1/202413:05EDGAR2Form 8-K - Current report
08/1/202413:00BWImmunome Exclusively Licenses Zentalis ROR1 Antibody-Drug..
04/1/202423:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/1/202414:00BWImmunome Appoints Phil Roberts as Chief Technical Officer
03/1/202414:00BWImmunome to Present at the 42nd Annual J.P. Morgan..
02/1/202414:05EDGAR2Form 8-K - Current report
02/1/202414:00BWImmunome Appoints Carol A. Schafer to Board of Directors
29/12/202323:00EDGAR2Form 8-K - Current report
26/12/202314:35EDGAR2Form 8-K - Current report
26/12/202314:30GLOBEAtreca Announces Asset Purchase Agreement for Sale of..
16/12/202301:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202303:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
22/11/202322:02EDGAR2Form 8-K/A - Current report: [Amend]
16/11/202322:08EDGAR2Form S-3 - Registration statement under Securities Act of..
15/11/202312:03EDGAR2Form 8-K - Current report
10/11/202314:00BWImmunome to Present at the Stifel 2023 Healthcare Conference
09/11/202322:52EDGAR2Form 8-K - Current report
09/11/202314:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202314:00BWImmunome Reports Third Quarter 2023 Financial Results
08/11/202314:30EDGAR2Form 8-K - Current report
08/11/202314:00BWImmunome Appoints Jean-Jacques Bienaimé to Board of..
31/10/202323:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202323:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202314:00BWImmunome Appoints Bob Lechleider, M.D., as Chief Medical..

Dernières Valeurs Consultées

NASDAQ
IMNM
Immunome
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés